Acuta Capital Partners’s Sutro Biopharma STRO Stock Holding History
Bought
Maintained
Sold
Other funds holding STRO
KCM
Acuta Capital Partners's STRO Position: Q3 2026 in Review
Acuta Capital Partners reduced its Sutro Biopharma (STRO) stake by 91% in Q3 2026, selling an estimated $5.41M and leaving 25,290 shares worth $407K. The position accounts for 0.31% of the portfolio, ranked #32.
Acuta Capital Partners first reported a position in STRO in Q4 2018 and has held it in 6 quarters since. The position peaked at $8.97M in Q2 2026. 104 funds tracked by Wall St. Rank hold STRO as of Q3 2026.
- Acuta Capital Partners held 25,290 shares of Sutro Biopharma worth $407K as of Q3 2026.
- Acuta Capital Partners sold 244,961 Sutro Biopharma shares in Q3 2026, an estimated $5.41M.
- Sutro Biopharma made up 0.31% of Acuta Capital Partners's portfolio in Q3 2026, its #32 holding.
- Acuta Capital Partners first reported a position in Sutro Biopharma in Q4 2018 and has held it in 6 quarters since.
- Acuta Capital Partners's Sutro Biopharma position peaked at $8.97M in Q2 2026.
- 104 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2026.
Based on Acuta Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.